Evidence map›Paper›PMID 35266095›Full record

ArticleCEN case reports2022

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection.

Hiroko Beppu, Toshie Ogawa, Masahiro Ishikane, Tomoko Kawanishi, Tatsuya Fukuda, Lubuna Sato, Akihiro Matsunaga, Kenji Maeda, Daisuke Katagiri, Yukihito Ishizaka and 6 more

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Hiroko BeppuDepartment of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan. korohipube@gmail.com.ORCID 0000-0002-6872-2857
Toshie OgawaDepartment of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan.
Masahiro IshikaneDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Tomoko KawanishiDepartment of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan.
Tatsuya FukudaDepartment of Endocrinology and Metabolism, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan.
Lubuna SatoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Akihiro MatsunagaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Kenji MaedaDepartment of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Daisuke KatagiriDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Yukihito IshizakaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Fumihiko YasuiDepartment of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Michinori KoharaDepartment of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kan KikuchiDivision of Nephrology, Shimoochiai Clinic, Tokyo, Japan.
Sachiko WakaiDepartment of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan.
National Center for Global Health and Medicine · JPOhkubo Hospital · JPTokyo Metropolitan Institute of Medical Science · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralHumansImmunoglobulin GMaleReinfectionRenal DialysisSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralImmunoglobulin GCOVID-19End-stage renal diseaseHemodialysisReinfectionSevere acute respiratory syndrome coronavirus 2 antibodies

Identifiers

PMID35266095
PMCPMC8906520
OpenAlexW4220988599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.